The treatment of Celiac Disease & Emphysema with vitamins

Celiac Disease and Emphysema: Mitamins custom make quality formulas for the treatment of Celiac Disease & Emphysema with vitamins. A Celiac Disease & Emphysema formula will be made to suit you, using quality brand name ingredients. Mitamins produce custom made vitamin and supplement formulas to suit your individual health needs conveniently in one formula, one bottle and one dosage. For assistance, call toll free: 1-866-585-1390
Your Supplements Facts - Covers the formulas above
Supplement Facts

Specially Formulated for: Celiac Disease and Emphysema

  • Amount Per Serving
    % DV
    Vitamin A
    2500
    IU
    50%
    Vitamin D
    100
    IU
    25%
    Vitamin E
    100
    IU
    333%
    Vitamin K
    10
    mcg
    13%
    Vitamin B6
    50
    mg
    2500%
    Folate
    400
    mcg
    100%
    Vitamin B12
    125
    mcg
    2083%
    Calcium
    100
    mg
    10%
    Magnesium
    50
    mg
    13%
    Zinc
    10
    mg
    67%
  • Amount Per Serving
    % DV
    Flax Seed Powder
    50
    mg
    *
    Astragalus Extract
    50
    mg
    *
    Ginkgo Extract
    40
    mg
    *
    Grape Seed Extract
    50
    mg
    *
    Green Tea Extract
    50
    mg
    *
    L-Glutathione Reduced
    50
    mg
    *
    N-Acetyl L-Cysteine
    100
    mg
    *
    L-Glutamine
    50
    mg
    *
    Amino Acid Mix
    50
    mg
    *
    * Daily Value (DV) not established
Name Your Supplement Bottle - Just how you like it
The current default name is: 
 
(Click in box to change)
Your Perfect Supplement - Custom-made just for you
Formulas form 35 Years of Medical Practice
Celiac Disease and Emphysema
Serving Size:4-5

Celiac Disease and Emphysema Formulas Details

Customize Your Supplements - Check all that apply
4A Select additional condition(s) you want to address:


4B Select all the medication(s) you are taking:
If your concern or medication is not listed here, use our Formulator, which covers 680 concerns and 1600 drugs, Click here!
Latest Health Related News:
Aranesp(R) Study Showing No Negative Impact On Survival In SCLC Presented At World Conference On Lung Cancer
Amgen (NASDAQ:AMGN) presented the results from a randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of Aranesp(R) (darbepoetin alfa) in previously untreated patients with extensive-stage small-cell lung cancer (SCLC) receiving chemotherapy ("the 145 study") on Monday, Sept. 3 at the 2007 World Conference on Lung Cancer in Seoul, Korea.
FDA Issues Approvable Letter For RISPERDAL(R) To Treat Adolescents With Schizophrenia And Children And Adolescents With Bipolar Mania
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced it has received an approvable letter from the U.S. Food and Drug Administration (FDA) regarding two supplemental New Drug Applications (sNDA) for RISPERDAL(R) (risperidone), filed on Dec. 21, 2006.
This information concerning the support of Celiac Disease and Emphysema treatments provide basic knowledge which should always be discussed with your own health practitioner.
Any Questions, Call Us Toll Free: 1-866-585-1390
Live Chat System

manufactured In USA

  verisign          Trust E Finalmark

Custom Vitamins and Nutritional Supplements for Supporting Age-Related Cognitive Decline and Aging Treatments